NextCure, Inc. (NXTC) News
Filter NXTC News Items
NXTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NXTC News Highlights
- For NXTC, its 30 day story count is now at 4.
- Over the past 11 days, the trend for NXTC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NXTC are DEC, MD and MG.
Latest NXTC News From Around the Web
Below are the latest news stories about NEXTCURE INC that investors may wish to consider to help them evaluate NXTC as an investment opportunity.
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingNextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryBELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats” in JMBR Plus, a journal of the American Society for Bone and Mineral Research |
NextCure (NXTC) Down on Shelving Plans to Develop CandidateNextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same. |
NextCure Provides Year-End Clinical Pipeline UpdatesBELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline. NC410 (LAIR-2 fusion) The Phase 1b combination trial of NC410 with pembrolizumab is ongoing.Given evidence of clinical activity to date, additional patients are being added to the 100 mg cohort o |
NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceBELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET. A live audio webcast will be available through the Investors section of |
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNew publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modelingUpdate for ongoing Phase 1a clinical trial is expected in the fourth quarter of 2023 BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and ot |
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to BuyNextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
NextCure Inc (NXTC) Reports Q3 2023 Financial ResultsCompany's R&D and G&A Expenses Decrease Year-Over-Year |
NextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsPhase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year endCash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported third quarter 2023 f |
We Think NextCure (NASDAQ:NXTC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |